However, Sacilotto et al. conducted a comprehensive evaluation of the in vitro inhibitory potential of LSD1 inhibitors at clinical stages and found that SP-2577 had minimal effects on AML markers and did not exhibit satisfactory targeting of LSD1, thereby raising doubts about the efficacy of reversible LSD1 inhibitors in the treatment of AML (Sacilotto et al., 2021; Baby et al., 2023). This evidence concerns the gene KDM1A and acute myeloid leukemia.